Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
Part of paid clinical trials in Ann Arbor, Michigan.
- Sponsor
- University of Michigan
- Study ID
- NCT06300697
- Status
- Recruiting
Conditions
- Atopic Dermatitis
- Food Allergy
- Healthy
Eligibility Criteria
- Sex
- ALL
- Age
- 10 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Data and biospecimen collection — OTHEREnrolled participants will have health-related information and blood specimens collected.
- Skin biopsies — OTHERParticipants will be asked to provide one or two skin biopsies (days 1 and 2) from the forearm, unless the participant is a healthy child (no food allergy and no atopic dermatitis), in which case there will be no skin biopsy.
- Oral Food Challenge (OFC) procedures — OTHERParticipants will have the choice of consenting to an OFC (approximately 2-4 hours) to peanut, tree nut, egg, milk, or sesame. If there is no allergy history, the study team will conduct an oral food challenge to one of the choices. The OFC will occur in the clinical research area. and done the same as a clinical care OFC. A transepidermal water loss monitor will be applied to participant's arm with a sticky pad and will stay on the arm for the challenge. Food doses will be given in small amounts that increase in size up to a defined single serving of the food based upon the participants age/size. The OFC will proceed until a full dose is consumed without symptoms, or until anaphylaxis occurs. Depending upon the participant's reaction to the oral food challenge, the participant may be requested to return the next day for a research visit that would take less than an hour. The 24-hour post oral food challenge visit will include an interview to assess condition and a blood sample.
Study Details
This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future. This is a mechanistic study consisting of obtaining blood and skin samples from participants at baseline. Individuals may also undergo a clinically indicated oral food challenge and have blood and skin samples collected at various times during the oral food challenge. This study will create a molecular map of the pathology of atopic dermatitis and food allergy. This information will be deployed to evaluate the hypothesis that atopic dermatitis and food allergy share unique genetic transcriptional signals in which the study team can then further analyze pathological pathways and cell types.
Key Dates
- Start date
- Feb 15, 2024
- Status verified
- Nov 2025
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- BASIC_SCIENCE
Arms
- Other: Control group AdultParticipation will be approximately 14 days after enrollment.
- Other: Food allergy-only groupParticipation will be approximately 14 days after enrollment.
- Other: Food allergy plus atopic dermatitis groupParticipation will be approximately 14 days after enrollment.
- Other: Atopic dermatitis without food allergy groupParticipation will be approximately 14 days after enrollment.
- Other: Control Group less than 18 years oldParticipation will be approximately 14 days after enrollment.
Primary Outcome Measure
Anaphylaxis occurrence rates in each group [ Time Frame: Approximately 4 hours (Day 1 during the food challenge) ]
Central Contacts
- Bridgette Kaul734-647-8284
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Michigan | Ann Arbor | Michigan | 48109 | Chase Schuler, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Ann Arbor, MI
Related Studies
- Ethnic Differences in Mechanisms of Action of DupilumabPHASE4 · Recruiting · University of Michigan · Ann Arbor, Michigan
- Identification of Biomarkers for Stress Vulnerability and ResilienceRecruiting · University of Michigan · Ann Arbor, Michigan
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPHASE2 · Recruiting · Pfizer · Birmingham, Alabama